공시 • Jun 09
Stella Pharma Corporation to Report Q1, 2027 Results on Aug 06, 2026 Stella Pharma Corporation announced that they will report Q1, 2027 results on Aug 06, 2026 Reported Earnings • May 17
Full year 2026 earnings released: JP¥22.93 loss per share (vs JP¥4.19 loss in FY 2025) Full year 2026 results: JP¥22.93 loss per share (further deteriorated from JP¥4.19 loss in FY 2025). Net loss: JP¥780.0m (loss widened 457% from FY 2025). Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. New Risk • May 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.4b (US$91.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risk Market cap is less than US$100m (JP¥14.4b market cap, or US$91.2m). 공시 • May 13
Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026 Stella Pharma Corporation, Annual General Meeting, Jun 24, 2026. Reported Earnings • Feb 14
Third quarter 2026 earnings released: JP¥6.03 loss per share (vs JP¥3.09 loss in 3Q 2025) Third quarter 2026 results: JP¥6.03 loss per share (further deteriorated from JP¥3.09 loss in 3Q 2025). Revenue: JP¥61.0m (down 28% from 3Q 2025). Net loss: JP¥205.0m (loss widened 95% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Nov 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Market cap is less than US$100m (JP¥8.51b market cap, or US$54.4m). Reported Earnings • Nov 17
Second quarter 2026 earnings released: JP¥4.44 loss per share (vs JP¥3.16 loss in 2Q 2025) Second quarter 2026 results: JP¥4.44 loss per share (further deteriorated from JP¥3.16 loss in 2Q 2025). Revenue: JP¥108.0m (flat on 2Q 2025). Net loss: JP¥151.0m (loss widened 41% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 08
First quarter 2026 earnings released: JP¥4.59 loss per share (vs JP¥5.09 loss in 1Q 2025) First quarter 2026 results: JP¥4.59 loss per share (improved from JP¥5.09 loss in 1Q 2025). Revenue: JP¥92.0m (up 51% from 1Q 2025). Net loss: JP¥156.0m (loss narrowed 3.1% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jun 09
Now 24% overvalued Over the last 90 days, the stock has fallen 4.1% to JP¥371. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%. Buy Or Sell Opportunity • May 23
Now 21% overvalued Over the last 90 days, the stock has fallen 28% to JP¥360. The fair value is estimated to be JP¥299, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 55% over the last 3 years. Earnings per share has grown by 17%. Reported Earnings • May 12
Full year 2025 earnings released: JP¥4.19 loss per share (vs JP¥24.63 loss in FY 2024) Full year 2025 results: JP¥4.19 loss per share (improved from JP¥24.63 loss in FY 2024). Revenue: JP¥961.0m (up 257% from FY 2024). Net loss: JP¥140.0m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. 공시 • May 09
Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025 Stella Pharma Corporation, Annual General Meeting, Jun 24, 2025. 공시 • Mar 05
Stella Pharma Corporation to Report Fiscal Year 2025 Results on May 09, 2025 Stella Pharma Corporation announced that they will report fiscal year 2025 results on May 09, 2025 Reported Earnings • Feb 14
Third quarter 2025 earnings released: JP¥3.09 loss per share (vs JP¥5.25 loss in 3Q 2024) Third quarter 2025 results: JP¥3.09 loss per share (improved from JP¥5.25 loss in 3Q 2024). Net loss: JP¥105.0m (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Feb 03
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.5b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Revenue is less than US$5m (JP¥285m revenue, or US$1.8m). Market cap is less than US$100m (JP¥15.5b market cap, or US$99.9m). 공시 • Jan 03
Stella Pharma Corporation to Report Q3, 2025 Results on Feb 12, 2025 Stella Pharma Corporation announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 10
Second quarter 2025 earnings released: JP¥3.16 loss per share (vs JP¥4.51 loss in 2Q 2024) Second quarter 2025 results: JP¥3.16 loss per share (improved from JP¥4.51 loss in 2Q 2024). Net loss: JP¥107.0m (loss narrowed 24% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. 공시 • Sep 27
Stella Pharma Corporation to Report Q2, 2025 Results on Nov 08, 2024 Stella Pharma Corporation announced that they will report Q2, 2025 results on Nov 08, 2024 공시 • Jun 22
Stella Pharma Corporation to Report Q1, 2025 Results on Aug 07, 2024 Stella Pharma Corporation announced that they will report Q1, 2025 results on Aug 07, 2024 Reported Earnings • May 14
Full year 2024 earnings released: JP¥24.63 loss per share (vs JP¥26.94 loss in FY 2023) Full year 2024 results: JP¥24.63 loss per share (improved from JP¥26.94 loss in FY 2023). Net loss: JP¥763.0m (loss narrowed 1.9% from FY 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. 공시 • May 12
Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024 Stella Pharma Corporation, Annual General Meeting, Jun 25, 2024. 공시 • Mar 24
Stella Pharma Corporation to Report Fiscal Year 2024 Results on May 10, 2024 Stella Pharma Corporation announced that they will report fiscal year 2024 results on May 10, 2024 Reported Earnings • Feb 15
Third quarter 2024 earnings released: JP¥5.25 loss per share (vs JP¥4.85 loss in 3Q 2023) Third quarter 2024 results: JP¥5.25 loss per share (further deteriorated from JP¥4.85 loss in 3Q 2023). Net loss: JP¥164.0m (loss widened 18% from 3Q 2023). 공시 • Dec 27
Stella Pharma Corporation to Report Q3, 2024 Results on Feb 13, 2024 Stella Pharma Corporation announced that they will report Q3, 2024 results on Feb 13, 2024 Reported Earnings • Nov 10
Second quarter 2024 earnings released: JP¥4.51 loss per share (vs JP¥5.16 loss in 2Q 2023) Second quarter 2024 results: JP¥4.51 loss per share (improved from JP¥5.16 loss in 2Q 2023). Net loss: JP¥140.0m (loss narrowed 5.4% from 2Q 2023). 공시 • Sep 27
Stella Pharma Corporation to Report Q2, 2024 Results on Nov 09, 2023 Stella Pharma Corporation announced that they will report Q2, 2024 results on Nov 09, 2023 Reported Earnings • Aug 10
First quarter 2024 earnings released: JP¥5.43 loss per share (vs JP¥6.84 loss in 1Q 2023) First quarter 2024 results: JP¥5.43 loss per share (improved from JP¥6.84 loss in 1Q 2023). Net loss: JP¥165.0m (loss narrowed 16% from 1Q 2023). 공시 • Jun 28
Stella Pharma Corporation to Report Q1, 2024 Results on Aug 09, 2023 Stella Pharma Corporation announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 10
Full year 2023 earnings released: JP¥26.94 loss per share (vs JP¥27.31 loss in FY 2022) Full year 2023 results: JP¥26.94 loss per share. Net loss: JP¥778.0m (loss widened 1.4% from FY 2022). 공시 • May 10
Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023 Stella Pharma Corporation, Annual General Meeting, Jun 27, 2023. Reported Earnings • Feb 12
Third quarter 2023 earnings released: JP¥4.85 loss per share (vs JP¥5.31 loss in 3Q 2022) Third quarter 2023 results: JP¥4.85 loss per share (improved from JP¥5.31 loss in 3Q 2022). Net loss: JP¥139.0m (loss narrowed 8.6% from 3Q 2022). 공시 • Feb 11
Stella Pharma Corporation Provides Earnings Guidance for the Full Year Ending March 31, 2023 Stella Pharma Corporation provided earnings guidance for the full year ending March 31, 2023. For the year, the company expects net sales of ¥220 million, operating loss of ¥850 million, loss of ¥823 million and loss per share of ¥28.55. 공시 • Dec 26
Stella Pharma Corporation to Report Q3, 2023 Results on Feb 10, 2023 Stella Pharma Corporation announced that they will report Q3, 2023 results on Feb 10, 2023 Reported Earnings • Nov 19
First half 2023 earnings released First half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022). Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. No highly experienced directors. 2 independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Nov 11
First half 2023 earnings released First half 2023 results: JP¥12.00 loss per share. Net loss: JP¥344.0m (flat on 1H 2022). 공시 • Sep 24
Stella Pharma Corporation to Report Q2, 2023 Results on Nov 11, 2022 Stella Pharma Corporation announced that they will report Q2, 2023 results on Nov 11, 2022 공시 • May 12
Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022 Stella Pharma Corporation, Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 공시 • Apr 08
Stella Pharma Corporation to Report Fiscal Year 2022 Results on May 10, 2022 Stella Pharma Corporation announced that they will report fiscal year 2022 results on May 10, 2022